The promiscuous, multi-kinase inhibitor sorafenib, for example, can target PDAC CSCs, suppressing colony outgrowth, tumorsphere formation, ALDH1 activity, and tumor-initiating capacity [110]. This evidence concerns the gene ALDH1A1 and neoplasm.